Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  Google Scholar 

  2. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51.

    Article  CAS  Google Scholar 

  3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.

    Article  CAS  Google Scholar 

  4. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.

    Article  Google Scholar 

  5. Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S, Boland GM. Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08657-6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Daan Jan Willem Rauwerdink & Genevieve Marie Boland MD, PhD

  2. Department of Surgery, Leiden University Medical Center, Leiden University, Leiden, RC, The Netherlands

    Daan Jan Willem Rauwerdink

Authors
  1. Daan Jan Willem Rauwerdink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Genevieve Marie Boland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Genevieve Marie Boland MD, PhD.

Ethics declarations

Disclosures

Genevieve Boland has sponsored research agreements with Takeda Oncology, Palleon Pharmaceuticals, and Olink Proteomics. She has received speakers’ honoraria from Novartis and Takeda Oncology. She has served on the scientific advisory board for Nektar Therapeutics and serves currently on their steering committee.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rauwerdink, D.J.W., Boland, G.M. ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. Ann Surg Oncol 27, 3498–3499 (2020). https://doi.org/10.1245/s10434-020-08663-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08663-8

Search

Navigation